IL-10 and CXCL10 in Urine May Predict Response to BCG Therapy in Bladder Cancer

May 15, 2020
Felix Guerrero-Ramos, PhD

Felix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.

Felix Guerrero-Ramos, PhD, urologist, Hospital Universitario 12 de Octubre, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin (BCG) in patients with bladder cancer.

Among 20 patients analyzed in this study, Guerrero-Ramos says a good correlation was observed between IL-10 and CXCL10 levels in urine samples compared with tissue, as well as the presence of M2 polarized macrophages. IL-10 also appeared to be higher in patients with primary tumors compared with patients who had recurred. This information will have some impact on the clinical setting, although it is not a big relevance, says Guerrero-Ramos. It is important to understand that higher IL-10 levels occur in primary tumors, not CXCL10.

The main outcome of this study was that patients who had responded to BCG had lower levels of both IL-10 and CXCL10 in their urine samples. Overall, Guerrero-Ramos believes that the identification of IL-10 and CXCL10 levels in urine is a good biomarker for prediction of response to BCG in patients with bladder cancer.

<< View more resources and information from the AUA Annual Meeting